Jörg Baumgarten

Title: Jörg Baumgarten: Innovator in Cytostatic Conjugates

Introduction

Jörg Baumgarten is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of cytostatics, focusing on tumor-specific actions through innovative linking units. With a total of 3 patents, his work has the potential to impact cancer treatment significantly.

Latest Patents

Baumgarten's latest patents include groundbreaking inventions such as "Cytostatic conjugates with integrin ligands." This invention relates to cytostatics that exhibit tumor-specific action due to their linkage to αβ-integrin antagonists via preferred linking units. These linking units can be selectively cleaved by elastase, an enzyme found in tumor tissue, ensuring stability in biological fluids while allowing for targeted action within tumor cells. Another significant patent is "Integrin-mediated drug targeting," which also focuses on cytostatics linked to αβ-integrin antagonists. This invention guarantees serum stability and desired intracellular action in tumor cells through enzymatic or hydrolytic cleavability.

Career Highlights

Throughout his career, Jörg Baumgarten has worked with prominent companies, including Bayer Aktiengesellschaft. His experience in these organizations has contributed to his expertise in developing innovative solutions in the pharmaceutical field.

Collaborations

Baumgarten has collaborated with notable colleagues such as Andreas Schoop and Hans-Georg Lerchen. These partnerships have likely enhanced his research and development efforts in the field of cytostatics.

Conclusion

Jörg Baumgarten's contributions to the field of cytostatics through his innovative patents demonstrate his commitment to advancing cancer treatment. His work continues to pave the way for more effective therapeutic options in oncology.